Skip to content
DataLookout
Menu

NCT07216482

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 35 versions: 34 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
    • Trial completed
    • Study completion date changed from estimate of Nov 5, 2026 to Oct 27, 2026
    • Secondary endpoints: details revised at 2 of 9 entries
    • Site details revised at 4 of 87 sites
  2. Minor Enrollment target: estimated 975 to confirmed 996
    • Study sites: 89 to 87
    • Primary completion date changed from estimate of Aug 12, 2026 to Aug 3, 2026
    v34
  3. Minor Primary completion moved earlier from Dec 2, 2026 to Aug 12, 2026
    • Study completion moved earlier from Mar 1, 2027 to Nov 5, 2026
    v33
  4. Minor Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 89 of 89 sites
    v32
  5. Minor Site details revised at 4 of 89 sitesv31
Show 28 earlier versionsHide 28 earlier versions
  1. Minor Site details revised at 11 of 89 sitesv30
  2. Minor Site details revised at 2 of 89 sitesv29
  3. Minor Site details revised at 38 of 89 sitesv28
  4. Minor Site details revised at 24 of 89 sitesv27
  5. Minor Site details revised at 4 of 89 sitesv26
  6. Minor Study sites: 88 to 89v25
  7. Minor Study sites revised (88)v24
  8. Minor Site details revised at 1 of 88 sitesv23
  9. Minor Study sites revised (88)v22
  10. Minor Study sites: 87 to 88v21
  11. Minor Study sites: 82 to 87v20
  12. Minor Study sites: 81 to 82v19
  13. Minor Study sites: 80 to 81v18
  14. Minor Study sites: 78 to 80v17
  15. Minor Study sites: 77 to 78v15
  16. Minor Study sites: 72 to 77v14
  17. Minor Study sites: 63 to 72v13
  18. Minor Study sites: 61 to 63v12
  19. Minor Study sites: 59 to 61v11
  20. Minor Study sites: 56 to 59v10
  21. Minor Study sites: 55 to 56v9
  22. Minor Study sites: 53 to 55v8
  23. Minor Study sites: 47 to 53v7
  24. Minor Study sites: 44 to 47v6
  25. Minor Study sites: 42 to 44v5
  26. Minor Study sites: 37 to 42v4
  27. Minor Study sites: 30 to 37v3
  28. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 30
    • Start date changed from estimate of Nov 19, 2025 to Nov 11, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Mean Percent Change from Baseline in LDL-C at Week 8 (Enlicitide + Rosuvastatin Versus Placebo)
Timeframe: Baseline and Week 8

Secondary (9)

Mean Percent Change from Baseline in LDL-C at Week 8
Mean Percent Change from Baseline in Apolipoprotein B (ApoB) at Week 8
Number of Participants with One or More Adverse Events (AEs)
Number of Participants who Discontinue Study Drug Due to One or More AEs
Mean Percent Change from Baseline in LDL-C at Week 12
Show 4 moreShow less
Mean Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C) at Week 8
Percent Change from Baseline in Lipoprotein (a) (Lp[a]) at Week 8
Percentage of Participants with LDL-C <70 mg/dL and ≥50% Reduction from Baseline at Week 8
Percentage of Participants with LDL-C <55 mg/dL and ≥50% Reduction from Baseline at Week 8

Arms and interventions

EnlicitideExperimental

Participants will receive enlicitide and a rosuvastatin-matching placebo. Both will be delivered orally once daily (QD) for up to 12 weeks.

Enlicitide + RosuvastatinExperimental

Participants will receive enlicitide and rosuvastatin. Both will be delivered orally QD for up to 12 weeks.

RosuvastatinActive comparator

Participants will receive rosuvastatin and an enlicitide-matching placebo. Both will be delivered orally QD for up to 12 weeks.

PlaceboPlacebo comparator

Participants will receive an enlicitide-matching placebo and a rosuvastatin-matching placebo. Placebos will be delivered orally QD for up to 12 weeks.

Drugs: Enlicitide, Rosuvastatin, Placebo for Enlicitide, Placebo for Rosuvastatin

Sites

87 sites in 11 countries

United States 35, Argentina 7, Australia 6, Canada 6, Turkey (Türkiye) 6, Brazil 5, Israel 5, New Zealand 5, United Kingdom 5, Hungary 4, Spain 3